A Review on Affordable Combinations in Type 2 Diabetes Care: Exploring the Cost-Effective Potential of Glipizide + Metformin and Glimepiride + Metformin + Pioglitazone

Management of type 2 diabetes mellitus (T2DM) largely relies on medication adherence of individuals with diabetes to achieve optimal glycemic control. The economic burden of diabetes could impede adherence, leading to a reduction in treatment efficacy and increased risk of complications. Furthermore...

Full description

Saved in:
Bibliographic Details
Published inCurēus (Palo Alto, CA) Vol. 16; no. 5; p. e59850
Main Authors Shaikh, Shehla, Vaidya, Vishal, Gupta, Amit, Kulkarni, Raghunath, Joshi, Ashok, Kulkarni, Medhinee, Sharma, Vidhe, Revankar, Santosh
Format Journal Article
LanguageEnglish
Published United States Springer Nature B.V 07.05.2024
Cureus
Subjects
Antidiabetics
Chronic illnesses
Combination therapy
Cost analysis
Diabetes
Drug dosages
Endocrinology/Diabetes/Metabolism
Expenditures
Hemoglobin
Internal Medicine
Metabolism
Mortality
Patient compliance
Pharmacoeconomics
Socioeconomic factors
India
sustainable healthcare
glipizide and metformin
glycemic control
cost-effective
combination drugs
diabetes mellitus
glimepiride with metformin and pioglitazone
affordability
Online AccessGet full text

Cover

More Information
Summary:Management of type 2 diabetes mellitus (T2DM) largely relies on medication adherence of individuals with diabetes to achieve optimal glycemic control. The economic burden of diabetes could impede adherence, leading to a reduction in treatment efficacy and increased risk of complications. Furthermore, monotherapy in diabetes is losing traction due to its ineffectiveness in achieving early and sustained optimal glycemic control in a significant proportion of the population. Hence, clinicians prefer combination treatment due to their improved efficacy and safety. Considering these factors, the current review highlights the safety and efficacy of the affordable combination therapies, a dual therapy, glipizide + metformin, and a triple-drug combination of glimepiride + metformin + pioglitazone and its applicability in the management of T2DM among individuals with diabetes in India.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.59850